Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study

Abstract

IntroductionIn our previous study investigating effects of luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, on 24-h glycemic variability by continuous glucose monitoring (CGM), luseogliflozin elicited parallel downward shifts in fasting and postprandial glucose levels. However, further review of individual patients’ data revealed that postprandial hyperglycemia was not reduced in some patients, while preprandial glucose was ameliorated in most patients. Therefore, we divided patients into two groups according to their postprandial glucose responses and conducted a post hoc subanalyses to elucidate which factors contributed to the differential effects of luseogliflozin.MethodsThirty-four Japanese type 2 diabetic patients in our previous randomized, double-blind, placebo-controlled, crossover study with 7-day luseogliflozin administration were divided into postprandial glucose responders (PGR, n = 23, ameliorated peak glucose) and postprandial glucose non-responders (PGNR; n = 11, non-ameliorated peak glucose). Baseline characteristics, variations in CGM-measured 24-h glucose levels, and other pharmacodynamic variabilities were compared.ResultsBaseline characteristics did not differ significantly between groups. Placebo-subtracted peak glucose was significantly lowered in PGR and significantly increased in PGNR (−43.8 and 17.9 mg/dL; both p < 0.05). Luseogliflozin significantly lowered “lowest glucose” (defined as the lowest level measured throughout a 24-h period) similarly in PGR and PGNR (−19.2 and −24.0 mg/dL; both p < 0.05), significantly reduced the mean amplitude of glucose excursions in PGR (−15.50 mg/dL; p < 0.05), and increased the area under the curve for plasma glucagon over 24 h in PGNR (median difference vs. placebo: 240 pg/mL h; p < 0.05). Luseogliflozin increased urinary glucose excretion (UGE) and decreased serum insulin by similar magnitudes in both groups.ConclusionsLuseogliflozin diminished glucose fluctuations in most patients by lowering peak glucose to a greater extent than lowest glucose. Luseogliflozin may also lower lowest glucose in patients whose peak glucose was not ameliorated despite increasing UGE. The glucagon increase in PGNR might explain its hypoglycemic effect on postprandial glucose.FundingTaisho Pharmaceutical Co., Ltd, Tokyo, Japan.Trial RegistrationJapicCTI-142548.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-016-0350-5) contains supplementary material, which is available to authorized users.

Effects of DPP-4 Inhibitors on Blood Glucose Variability in Japanese Patients with Type 2 Diabetes on Maintenance Hemodialysis: A Prospective Observational Exploratory Study

“…However, the changes between time points can be approximated using the slope of a linear mixed-effects model. Linear mixed-effects methods are used to fit the model to repeated-measures data such as those of CGM [ 55 ], in which measurements are obtained repeatedly over time or under different conditions. The model comprises repeated effects, fixed or covariate effects, and random effects, and the interactions among combinations of these as predictor variables.…”

Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2

“…Unfortunately, plasma insulin levels and the magnitude of insulin resistance were not described in that study. However, it has been shown that the use of the SGLT2i luseogliflozin reduced plasma insulin in type 2 diabetes (32). Given that the participants in the EMPA-REG OUTCOME trial had an average body mass index of 30.6 kg/m 2 at baseline and that the reduction in serum UA (observed as early as at 12 wk) was accompanied by a sharp decrease in hemoglobin A1C levels and in waist circumference (47), the hypouricemic effects of the SGLT2i may partly be attributable to reduced insulin levels.…”

Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management

“…Targeting GV has lond been recognized as most useful in treating T2DM patients in terms of both hyperglycemia management and risk reduction of vascular complications [41]. In this context, luseogliflozin has reportedly reduced glucose fluctuations in a randomized controlled trial in T2DM patients [42]. However, data are lacking with regard to other SGLT2i in that context.…”